Introduction
============

Recently, the global prevalence of myopia has been shown to be on the increase, worldwide.[@b1-opth-11-1009] According to current trends, the international myopic burden is set to boom, with 4,578 million people or approximately half of the world population expected to be victims of this disorder.[@b2-opth-11-1009] In Pakistan, the prevalence of myopia among the adult population was found to be 36.5%.[@b3-opth-11-1009]

The dynamic and multifaceted development of myopia in the region, coupled with technological advances over time, has led to the growing utilization of contemporary avenues of treatment for this disorder. Refractive surgery, particularly laser-assisted in situ keratomileusis (LASIK), has shown promising results in this regard.[@b4-opth-11-1009],[@b5-opth-11-1009]

With the advent of Femto-LASIK, superior refractive outcomes in patients have been reported,[@b6-opth-11-1009] but not all researchers agree. Some show superior outcomes with the former,[@b7-opth-11-1009]--[@b10-opth-11-1009] others favor the use of a microkeratome,[@b11-opth-11-1009] and a few show no significant differences in either of the treatment modalities.[@b12-opth-11-1009],[@b13-opth-11-1009]

This large-scale retrospective study compares the refractive outcomes following two distinct LASIK modalities in a large cohort of patients. To date, most studies comparing outcomes of LASIK with a Hansatome microkeratome (HM) and femto-assisted laser (FAL) have been conducted in western, developed countries[@b7-opth-11-1009],[@b14-opth-11-1009] and have often compared outcomes in small sample sizes with limited refractive ranges.[@b12-opth-11-1009],[@b13-opth-11-1009],[@b15-opth-11-1009] To the best of our knowledge, this is the only study to assess the large-scale refractive outcomes of two distinct LASIK techniques in this region and one of the only in the world to include a wide range of refractive errors.

Methods
=======

Patients
--------

Thousand three-hundred sixty-six individual eyes of 687 patients were enrolled in this retrospective study, including 272 males and 415 females. Of this cohort, 1,137 eyes were treated with an HM and 229 with an FAL. The study period was from January 2013 to August 2016. All surgeries were conducted at the two centers of Hashmanis Hospital in Karachi, Pakistan. Three different surgeons took part in the HM group, while there was a single surgeon in the FAL cohort. Ethical approval for this retrospective study was granted by the Ethics Committee of the Hashmanis Hospital. Additionally, written informed consent for the surgery and inclusion in this study was obtained from all patients.

Inclusion/exclusion criteria
----------------------------

Prior to treatment, all individuals were assessed according to the study's inclusion/exclusion criteria. Individuals older than 18 years with a stable refraction, a central corneal thickness (CCT) greater than 480 μm, a presumed residual stromal bed of \>250 μm, and discontinued soft contact use for at least 1 week were deemed eligible. Informed consent was sought from all such individuals prior to surgery. Those with any ocular pathology, either active or residual, retinal pathologies including dystrophies or diabetic retinopathy, dry eyes with a Schirmer's test II value of less than 2 mm, and those who were immunocompromised, nursing, or pregnant were excluded.

Prior to surgery, all patients underwent routine examinations including uncorrected visual acuity (UCVA), best-corrected visual acuity (BCVA), cycloplegic and subjective refractive error, slit-lamp examination, dilated retinal exam, ultrasonic pachymetry, keratometry, and corneal topography.

LASIK procedure and postoperative care
--------------------------------------

We performed surgeries in both eyes using the same procedure. Both surgeries were performed using the wavelight EX 500 machine (Alcon, Ft Worth, TX, USA), which was wavefront optimized. An HM (Bausch & Lomb, Rochester, NY, USA) was used to create flaps in one group, while a wavelight FS 200 Laser machine (Alcon) was employed in the other group undergoing LASIK with an FAL. We measured the CCT on the apex of the cornea, preoperatively. Then, once the flap was created, a second measurement was taken to calculate the thickness of the underlying stroma intraoperatively. In both instances, the Pocket II ultrasonic pachymeter (Quantel Medical, Inc., Bozeman, MT, USA) was used. A 140 μm and 120 μm flap was used in the HM and FAL groups, respectively. In those under FAL, a tissue separator was used to raise the flap, and in both arms, a balanced salt solution was used to irrigate the eye once the flap was placed back after the procedure.

Following surgery, these postoperative measures were employed: artificial tears 4 times a day for 3 weeks; moxifloxacin eye drops 4 times a day for 10 days; and combination drops with tobramycin and dexamethasone 4 times a day for 10 days.

Patients were followed up at 1 month postoperatively to review refractive outcomes including UCVA, spherical equivalent (SE), and sphere and cylinder values. The target refractive outcome was emmetropia in all patients that was either greater than −12.00 diopters (D) or less than 4.00 D. For those exceeding this value, the target was the refractive error subtracted from these values. The target outcome in both instances was dependent on the keratometry reading. Accordingly, procedural efficacy index was calculated as the proportion of the mean postoperative UCVA to the mean preoperative BCVA. Predictability was defined as percentage of eyes achieving mean SE within ±1.00 D.

Patient satisfaction
--------------------

Patients were surveyed at the time of chart review and asked to rate their LASIK experience in the following classes: extremely satisfied, very satisfied, satisfied, and not satisfied.

Statistical analysis
--------------------

AppSheet was used to enter data into Google Sheet from which the data were subsequently imported into SPSS 16.0 (SPSS Inc., Chicago, IL, USA). All subsequent analysis was done on this software. Descriptive statistics was used to calculate the median and standard deviation of all values; median values were used, as these data were not normally distributed. The Mann--Whitney *U* test was used to compare the sphere, cylinder, and SE between the two modalities. Graphs were constructed using SPSS and Microsoft Excel (Microsoft Corp., Redmond, WA, USA).

Results
=======

Of the 1,366 eyes (687 patients) treated, 1,137 (570 patients) were in the HM group and 229 (117 patients) in the FAL. The mean age of patients in both groups was 25±5.8 and 27.0±7.3 years ([Table 1](#t1-opth-11-1009){ref-type="table"}), respectively.

Preoperative parameters included: sphere values of −4.3±2.8 D and −4.3±2.3 D; cylinder values of −1.0±1.0 D and −1.0±1.3 D; and SE values of −4.5±2.8 D and −4.5±2.5 D, among the HM and FAL groups, respectively ([Table 1](#t1-opth-11-1009){ref-type="table"}). No statistically significant difference existed in any of these values. [Figure 1](#f1-opth-11-1009){ref-type="fig"} displays the preoperative and postoperative astigmatism of the two treatment modalities. [Figure 2](#f2-opth-11-1009){ref-type="fig"}, on the other hand, shows the predicted versus the achieved SE.

Postoperatively, the refractive outcomes for HM and FAL included: sphere values of 0.0±1.28 and 0.3±0.7; cylinder values of −0.5±0.5 and −0.5±0.6; and SE values of −0.3±1.3 and 0.0±0.7, respectively ([Table 2](#t2-opth-11-1009){ref-type="table"}). All differences in postoperative values were found to be statistically signifi-cant with *P*-values \<0.001 ([Table 2](#t2-opth-11-1009){ref-type="table"}).

It was found that the FAL group yielded the most uniform outcomes in visual acuity, as almost all achieved a postoperative UCVA of 20/20 ([Figure 3](#f3-opth-11-1009){ref-type="fig"}), with a corresponding efficacy index of 1.00. This is in contrast with those in HM, which yielded a somewhat lower efficacy index of 0.84.

The postsurgical refractive outcomes demonstrated good predictability ([Figure 4](#f4-opth-11-1009){ref-type="fig"}), with 92.1% of eyes that had undergone FAL achieving a mean SE within 1.00 D of the intended value. The same was achieved in 82.2% of eyes treated with an HM.

Slightly more patients (93.3%) reported an overall level satisfaction in the FAL cohort, compared to HM (91.4%) ([Table 3](#t3-opth-11-1009){ref-type="table"}). The combined patient satisfaction rate was 91.8% for both procedures. 61.4% of patients were available for judging patient satisfaction in the HM and 64.1% in the FAL.

Discussion
==========

Our study measured refractive outcomes across 1,366 eyes, of which a majority underwent LASIK with an HM (n=1,137) and the remainder with an FAL (n=229). The median age of patients in each treatment group was 25.0±5.8 and 27.0±7.3, which may be reflective of the increasing myopic burden among younger individuals.[@b16-opth-11-1009]--[@b18-opth-11-1009] Moreover, the preoperative data was similar for both the groups as indicated by the insignificant *P*-values.

The FAL cohort had significantly superior outcomes in two refractive domains: cylinder and SE (*P*\<0.01). Sphere, on the other hand, showed better values in the HM group. This corresponded to a greater efficacy index among eyes treated with the FAL (n=1.00), compared with the HM (n=0.84). These results are consistent with Montes Mico et al's[@b7-opth-11-1009] findings, where efficacy index for eyes treated with an FAL and a microkeratome were 1.07 and 1.00, respectively. Superior postoperative UCVA outcomes in eyes that have undergone FAL over microkeratome have been documented in other studies as well.[@b9-opth-11-1009],[@b10-opth-11-1009] Pajic et al,[@b15-opth-11-1009] in a prospective, randomized, and paired-eye study, also reported a lower efficacy index among eyes treated with microkeratome. However, significant differences in visual acuity between the two groups were only seen till the end of the first postoperative week as the delay in visual recovery in eyes treated with a microkeratome was attributed to a minimal interface fluid accumulation.[@b15-opth-11-1009] Our study, with a longer postoperative follow-up, shows a greater efficacy index in FAL at 1 month.

Interestingly, the aforementioned study correlated the lower efficacy index of eyes treated with microkeratome to the deviation in achieved versus intended flap thickness.[@b15-opth-11-1009] Several studies have shown that flaps produced using Femto-LASIK are more predictable, thinner, and have a favorable planar shape.[@b19-opth-11-1009]--[@b22-opth-11-1009] However, it is unclear whether the desirable flap properties translate into superior visual outcomes. Xia et al[@b8-opth-11-1009] found no significant differences in UCVA or BCVA in eyes treated with FAL or a mechanical microkeratome at any time postoperatively, despite achieving superior flap dimensions in the former group. Likewise, no significant differences in visual outcomes between the two flap cutting modalities were reported by Hashimoto et al[@b12-opth-11-1009] or Patel et al[@b13-opth-11-1009] in two separate randomized, controlled, paired-eye studies. However, the latter study reported greater flap thickness in eyes treated with Femto-LASIK, instead of blade LASIK, although the difference was not significant. One study was found to report a greater procedural efficacy in eyes treated with microkeratome LASIK over Femto LASIK.[@b11-opth-11-1009]

Given the uncertainty surrounding the subject matter, meta-analyses have been conducted by Zhang et al[@b14-opth-11-1009] and Chen et al[@b23-opth-11-1009] to evaluate refractive outcomes of the two modalities. Neither of these reported any significant differences in efficacy, although a better predictability was documented by Chen et al.[@b23-opth-11-1009] In addition, both had conflicting reports on the prevalence of higher-order aberrations (HOAs) with Zhang et al[@b14-opth-11-1009] reporting significantly fewer HOAs in eyes that have undergone FAL, and Chen et al[@b23-opth-11-1009] reporting no significant differences in either group.

In our setting, eyes treated with FAL showed a greater procedural predictability of 92.1%, as opposed to 82.2% predictability of eyes treated with LASIK using an HM. These findings are consistent with those of other studies,[@b7-opth-11-1009],[@b23-opth-11-1009]--[@b25-opth-11-1009] and may be reflective of faster visual recoveries associated with Femto-LASIK.[@b24-opth-11-1009]

Our study also assessed the reported satisfaction levels of patients postoperatively. It was found that both treatment modalities were received with high levels of satisfaction ([Table 3](#t3-opth-11-1009){ref-type="table"}): 91.4% reported satisfaction in the HM group and 93.3% in the FAL cohort. Similar high levels have also been reported in a previous study.[@b26-opth-11-1009]

Limitations
===========

This was a retrospective, observational study, and so all limitations associated with such methods apply. Additionally, our study was confined to the assessment of refractive outcomes following surgery, and we could not evaluate other pertinent outcomes like HOAs or contrast sensitivity. Also, our study did not report the flap thicknesses achieved with either treatment modality. Finally, we only had a 1 month follow-up and therefore cannot comment on the long-term effects of the procedure.

We recommend performing prospective studies where one surgeon performs surgeries on both modalities to get a more direct comparison. Such a model will account for any changes based on the skill of the surgeon.

Conclusion
==========

We reported superior refractive outcomes in LASIK performed with an FAL as compared to one with an HM. Femto-LASIK also showed greater procedural efficacy and predictability in this large cohort of Pakistani patients. Additionally, slightly higher levels of patient satisfaction were reported in the FAL group.

We would like to thank Dr Azfar Nafees and Dr Khaliq ur Rehman for providing their surgical data for use in this study.
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![Comparison of astigmatism.\
**Notes:** (**A**) Hansatome microkeratome; (**B**) femto-assisted laser.](opth-11-1009Fig1){#f1-opth-11-1009}

![Comparison of attempted and achieved SE.\
**Notes:** (**A**) Hansatome microkeratome; (**B**) femto-assisted laser.\
**Abbreviations:** postop, postoperative; SE, spherical equivalent.](opth-11-1009Fig2){#f2-opth-11-1009}

![Comparison of postoperative UCVA and preoperative BCVA.\
**Notes:** (**A**) Hansatome microkeratome; (**B**) femto-assisted laser.\
**Abbreviations:** UCVA, uncorrected visual acuity; BCVA, best-corrected visual acuity.](opth-11-1009Fig3){#f3-opth-11-1009}

![Comparison of refractive outcomes.\
**Notes:** (**A**) Hansatome microkeratome; (**B**) femto-assisted laser.](opth-11-1009Fig4){#f4-opth-11-1009}

###### 

Preoperative data

  Variable                     HM (n=1,137[a](#tfn1-opth-11-1009){ref-type="table-fn"})   FAL (n=229[a](#tfn1-opth-11-1009){ref-type="table-fn"})   *P*-value
  ---------------------------- ---------------------------------------------------------- --------------------------------------------------------- -----------
  Age (years)                  25.0±5.8 (18.0 to 50.0)                                    27.0±7.3 (18.0 to 52.0)                                   
  Gender, eyes (male/female)   474/663                                                    72/157                                                    
  Sphere (D)                   4.3±2.8 (−19.0 to 7.0)                                     −4.3±2.3 (−9.8 to 6.8)                                    0.656
  Cylinder (D)                 −1.0±1.0 (−6.0 to 5.0)                                     −1.0±1.3 (−12.8 to 3.3)                                   0.713
  SE (D)                       −4.5±2.8 (−19.5 to 8.0)                                    −4.5±2.5 (−13.4 to 8.0)                                   0.977

**Note:**

Number of eyes.

**Abbreviations:** D, diopters; FAL, femto-assisted laser; HM, Hansatome microkeratome; SE, spherical equivalent.

###### 

Postoperative data

  Variable       HM (n=1,137[a](#tfn3-opth-11-1009){ref-type="table-fn"})   FAL (n=229[a](#tfn3-opth-11-1009){ref-type="table-fn"})   *P*-value
  -------------- ---------------------------------------------------------- --------------------------------------------------------- -----------
  Sphere (D)     0.0±1.28 (−10.8 to 6.8)                                    0.3±0.7 (−5.5 to 1.8)                                     \<0.001
  Cylinder (D)   −0.5±0.5 (−4.5 to 1.5)                                     −0.5±0.6 (−5.0 to 1.0)                                    \<0.001
  SE (D)         −0.3±1.3 (−11.6 to 6.8)                                    0.0±0.7 (−6.0 to 1.6)                                     \<0.001

**Note:**

Number of eyes.

**Abbreviations:** D, diopters; FAL, femto-assisted laser; HM, Hansatome microkeratome; SE, spherical equivalent.

###### 

Patient satisfaction

  Satisfaction level    HM (n=350[a](#tfn5-opth-11-1009){ref-type="table-fn"})   FAL (n=75[a](#tfn5-opth-11-1009){ref-type="table-fn"})        
  --------------------- -------------------------------------------------------- -------------------------------------------------------- ---- ------
  Extremely satisfied   57                                                       16.3                                                     10   13.3
  Very satisfied        102                                                      29.1                                                     30   40.0
  Satisfied             161                                                      46.0                                                     30   40.0
  Not satisfied         30                                                       8.6                                                      5    6.7

**Note:**

Number of eyes.

**Abbreviations:** FAL, femto-assisted laser; HM, Hansatome microkeratome.
